CN Patent

CN111712511B — 澳瑞他汀e衍生物的白蛋白结合产物

Assigned to LadRx Corp · Expires 2024-07-16 · 2y expired

What this patent protects

本公开提供了澳瑞他汀E衍生物的白蛋白结合前药及其用途。

USPTO Abstract

本公开提供了澳瑞他汀E衍生物的白蛋白结合前药及其用途。

Drugs covered by this patent

Briviact (BRIVARACETAM) · UCB

Patent Metadata

Patent number: CN111712511B
Jurisdiction: CN
Classification: —
Expires: 2024-07-16
Drug substance claim: No
Drug product claim: No
Assignee: LadRx Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.